According to the latest filing from the U.S. Securities and Exchange Commission (SEC), some existing shareholders of Neuronetics Inc. plan to sell up to 20.7 million shares of the company's common stock.

This sale is initiated independently by the selling shareholders, and the company itself will not gain any profit from this transaction. This move may affect the number of circulating shares in the market, but the specific terms and timing of the sale will be determined based on market conditions and regulatory requirements. Investors should pay attention to the detailed information disclosed later in order to assess its potential impact on the equity structure and stock price.